Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024
March 28, 2024 07:00 ET
|
Purple Biotech Ltd.
NT219 found to suppress cancer stem cells that promote drug resistance to KRASG12C and KRASG12D inhibitors and solid tumor recurrence Potential biomarkers for treatment with NT219 detected in...
Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
March 14, 2024 07:30 ET
|
Purple Biotech Ltd.
Contribution of NK cells engager arm and conditionally activated T cell engager demonstrated Cleavable capping technology confines therapeutic activity to the local tumor micro environment which...
Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results
March 05, 2024 07:55 ET
|
Purple Biotech Ltd.
REHOVOT, Israel, March 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that...
Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024
February 27, 2024 07:00 ET
|
Purple Biotech Ltd.
NT219 was well tolerated Anti-tumor activity at relevant higher dose levels observed with 29% Objective Response Rate (ORR) and 71% Disease Control Rate (DCR) REHOVOT, Israel, Feb. 27, 2024...
Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial
February 13, 2024 07:00 ET
|
Purple Biotech Ltd.
NT219 recommended dose established, anti-tumor activity demonstrated REHOVOT, Israel, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd.("Purple Biotech" or "the Company") (NASDAQ/TASE:...
Purple Biotech Reaches Recommended Phase 2 Dose for NT219
February 01, 2024 07:30 ET
|
Purple Biotech Ltd.
REHOVOT, Israel, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that...
Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors
December 20, 2023 08:05 ET
|
Purple Biotech Ltd.
Dr. Margolin brings 35 years of expertise in biotechnology, pharma, and venture capital Purple Biotech also announces the resignation of Mr. Fabien Sebille, who served as the Company’s Chief Business...
Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial
December 14, 2023 06:50 ET
|
Purple Biotech Ltd.
This acceleration of recruitment is expected to result in earlier look at overall survival of patients REHOVOT, Israel, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple...
Purple Biotech Reports Third Quarter 2023 Financial Results
November 21, 2023 06:50 ET
|
Purple Biotech Ltd.
Initial Activity in Head and Neck Cancer Demonstrated in NT219 Phase 1/2 Dose Escalation Study Patients’ Enrollment in the Phase 2 Randomized CM24 Pancreatic Cancer Trial Ahead of Timelines Cash...
Purple Biotech Fortifies NT219 Patent Protection
November 02, 2023 07:00 ET
|
Purple Biotech Ltd.
New patent granted in China for pharmaceutical composition of NT219 expands IP protection REHOVOT, Israel, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the...